Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(8):514; doi:10.1093/jnci/djj176
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

NEWS

In Brief

The first 10% of the full text of this article appears below.

Thalidomide Used to Manage Myeloma Patients

Treatment with thalidomide increased survival time without side effects from medication or cancer recurrence in multiple myeloma patients when combined with the chemotherapy drug melphalan, according to a new study. However, the drug did not improve overall survival, and it had important adverse effects.

Bart Barlogie, M.D., Ph.D., of the University of Arkansas for Medical Sciences in Little Rock, and colleagues treated 668 . . . [Full Text of this Article]

U.S. Commercial Genetic Testing Misses Some Breast Cancer Mutations

Preventive Surgery Cost Effective for Women with BRCA1 or BRCA2 Mutations

Genetic Diversity in Tumor Cells Associated with Increased Risk of Cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?